VERA Vera Therapeutics, Inc.
Price Chart
Executive Summary
Vera Therapeutics announced alignment with the FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy. eGFR results are now expected in Q3 2026, with a supplemental Biologics License Application for full approval planned in Q4 2026, pending results. This accelerates the potential path to full approval for the company's lead asset.
Actionable Insight
The accelerated timeline for eGFR data (Q3 2026) and potential sBLA submission (Q4 2026) is a significant positive catalyst for VERA. Traders should monitor for the eGFR readout in Q3 2026, as positive results would de-risk the path to full approval and could drive substantial upside.
Key Facts
- Aligned with FDA on a revised, earlier ORIGIN 3 eGFR analysis plan for atacicept in IgA Nephropathy.
- eGFR results now expected in Q3 2026.
- Plans to submit supplemental Biologics License Application for full approval in Q4 2026, pending eGFR results.
- Filing date: June 2, 2026.
Financial Impact
No specific financial figures provided; the event accelerates a key regulatory catalyst for the company's only pipeline asset.
Risk Factors
- eGFR results may not support full approval, leading to significant downside.
- Regulatory timelines could slip, delaying the sBLA submission.
- Competing therapies in IgA Nephropathy could limit atacicept's commercial potential.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-252475 |
| Document: 0001193125-26-252475-index-headers.html | 0001193125-26-252475 |
| Document: 0001193125-26-252475-index.html | 0001193125-26-252475 |
| Document: 0001193125-26-252475.txt | 0001193125-26-252475 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
1d ago
|
Institutional Cluster
| $33.12 awaiting T+1 | awaiting T+1 | — | $34.26 (+3.44%) |
|
Jun 2, 2026
10d ago
|
8-K
| $31.26 $31.27 | ▲ +0.03% | ▲ +0.75% | $34.26 (+9.60%) |
|
Jun 2, 2026
10d ago
|
Press Release
| $31.26 $31.27 | ▲ +0.03% | ▲ +0.75% | $34.26 (+9.60%) |
|
May 7, 2026
5w ago
|
8-K
| $35.88 $36.19 | ▲ +0.86% | ▲ +0.03% | $34.26 (−4.52%) |
|
Feb 26, 2026
15w ago
|
8-K
| $42.35 $40.79 | ▼ −3.68% | ▼ −3.23% | $34.26 (−19.10%) |
|
Feb 23, 2026
15w ago
|
Insider Cluster
| $42.06 $42.37 | ▼ −0.74% | ▼ −0.00% | $34.26 (+18.54%) |
|
Feb 23, 2026
15w ago
|
Insider Cluster
| $42.06 $42.37 | ▼ −0.74% | ▼ −0.00% | $34.26 (+18.54%) |
|
Feb 23, 2026
15w ago
|
Insider Cluster
| $42.06 $42.37 | ▼ −0.74% | ▼ −0.00% | $34.26 (+18.54%) |
|
Feb 23, 2026
15w ago
|
Insider Cluster
| $42.06 $42.37 | ▼ −0.74% | ▼ −0.00% | $34.26 (+18.54%) |
|
Feb 23, 2026
15w ago
|
Insider Cluster
| $42.06 $42.37 | ▼ −0.74% | ▼ −0.00% | $34.26 (+18.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access